Elicio Therapeutics (ELTX) announced the completion of enrollment in the Phase 2 AMPLIFY-7P study. The randomized Phase 2 study is evaluating a 7-peptide formulation of ELI-002 in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma, PDAC, who are at high risk of relapse following surgery. Elicio previously reported AMPLIFY-7P Phase 1a study results demonstrating a favorable safety profile, robust T-cell responses, antigen spreading and encouraging preliminary DFS data in PDAC patients.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELTX:
- Elicio Therapeutics reports Q3 EPS ($1.39), consensus (73c)
- Elicio Therapeutics files to sell 3.44M shares of common stock for holders
- Elicio Therapeutics presents updated preliminary results from AMPLIFY-7P
- Elicio Therapeutics initiated with a Buy at JonesResearch
- Elicio Therapeutics Appoints Robert Connelly as Financial Officer
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue